.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Healthtrust
Chinese Patent Office
Dow
Fish and Richardson
Colorcon
Daiichi Sankyo
Express Scripts
Cerilliant
Farmers Insurance

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203171

« Back to Dashboard
NDA 203171 describes TELMISARTAN, which is a drug marketed by Hetero Labs Ltd V, Watson Labs, Aurobindo Pharma Ltd, Amneal Pharms, Zydus Pharms Usa Inc, Alembic Pharms Ltd, Glenmark Pharms Ltd, Inventia Hlthcare, Jubilant Generics, Sandoz Inc, Torrent Pharms Ltd, Prinston Inc, Mylan Pharms Inc, Lupin Ltd, and Macleods Pharms Ltd, and is included in twenty-three NDAs. It is available from fifteen suppliers. Additional details are available on the TELMISARTAN profile page.

The generic ingredient in TELMISARTAN is hydrochlorothiazide; telmisartan. There are thirty-one drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; telmisartan profile page.

Summary for NDA: 203171

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 203171

Mechanism of ActionAngiotensin 2 Receptor Antagonists

Suppliers and Packaging for NDA: 203171

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TELMISARTAN
telmisartan
 TABLET;ORAL 203171 ANDA Torrent Pharmaceuticals Limited 13668-156 13668-156-01 100 TABLET in 1 BOTTLE (13668-156-01)
TELMISARTAN
telmisartan
 TABLET;ORAL 203171 ANDA Torrent Pharmaceuticals Limited 13668-156 13668-156-30 30 TABLET in 1 BOTTLE (13668-156-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Jul 7, 2014TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Jul 7, 2014TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength80MG
Approval Date:Jul 7, 2014TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
UBS
Covington
Boehringer Ingelheim
Healthtrust
AstraZeneca
McKinsey
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot